Mycomax (Fluconazole)

• Mycomax (fluconazole) acts on fungal infections by inhibiting ergosterol synthesis, making it effective for several disease groups.
• Candidiasis (oropharyngeal, esophageal, vaginal, systemic): Eradicates Candida species and relieves associated symptoms.
• Cryptococcal meningitis: Provides systemic antifungal activity to treat central nervous system infection.
• Prophylaxis in immunocompromised patients: Prevents opportunistic fungal infections during periods of weakened immunity.

• Fluconazole inhibits the fungal cytochrome P450 enzyme 14α‑demethylase, a key step in ergosterol biosynthesis. By blocking ergosterol production, the drug disrupts fungal cell membrane formation, leading to increased membrane permeability and inhibition of fungal growth.

Adverse reactions may occur with fluconazole therapy.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: transient cranial discomfort.
• Diarrhea: loose stools, usually self‑limiting.
• Abdominal pain: cramping or discomfort.
• Rash: mild skin irritation.
• Elevated liver enzymes: mild, reversible changes in laboratory tests.

Serious or Rare Side Effects

• Hepatotoxicity: signs of liver injury such as jaundice.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiac arrhythmia: QT interval prolongation, especially with other risk factors.
• Anaphylaxis: rare, potentially life‑threatening allergic response.
• Hematologic abnormalities: neutropenia or thrombocytopenia.
• Visual disturbances: blurred vision or photophobia.

Before prescribing Mycomax, consider patient‑specific factors and monitor for potential risks.

• Liver function: assess baseline hepatic enzymes and monitor during therapy.
• Renal impairment: adjust dosing in severe kidney dysfunction.
• Pregnancy: evaluate risk‑benefit ratio; use only if clearly needed.
• Drug interactions: review concomitant medications for CYP450 interactions.
• Allergies: confirm no known hypersensitivity to azole antifungals.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Fluconazole may alter the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid)

• Cisapride: risk of serious cardiac arrhythmias.
• Pimozide: may cause severe QT prolongation.
• Certain statins (e.g., lovastatin, simvastatin): increased risk of myopathy.

Moderate Interactions (Monitor Closely)

• Warfarin: enhanced anticoagulant effect, monitor INR.
• Phenytoin: reduced phenytoin levels, monitor seizure control.
• Oral hypoglycemics (e.g., sulfonylureas): may increase hypoglycemia risk.
• Rifampin: decreased fluconazole efficacy, consider alternative therapy.